Ivor Campbell managing director of Stirlingshire-based Snedden Campbell explores the use of blood tests to diagnose cancer and questions whether the NHS’ latest approach is the right one.
The announcement that the NHS is taking part in a major new clinical trial for a blood test that could detect more than 50 cancers early has been welcomed as a potential, once-in-a-generation breakthrough.
The health service is partnering with Silicon Valley-based healthcare company Grail Inc in a randomised control trial involving up to 140,000 volunteers.